Annual report [Section 13 and 15(d), not S-K Item 405]

Cover

v3.26.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2025
Mar. 20, 2026
Jun. 30, 2025
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2025    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2025    
Current Fiscal Year End Date --12-31    
Entity File Number 000-24249    
Entity Registrant Name Interpace Biosciences, Inc.    
Entity Central Index Key 0001054102    
Entity Tax Identification Number 22-2919486    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One Waterview Plaza    
Entity Address, Address Line Two Suite 310    
Entity Address, Address Line Three 2001 Route 46    
Entity Address, City or Town Parsippany    
Entity Address, State or Province NJ    
Entity Address, Postal Zip Code 07054    
City Area Code (855)    
Local Phone Number 776-6419    
Title of 12(g) Security Common Stock, $0.01 par value per share    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 2,631,295
Entity Common Stock, Shares Outstanding   27,700,904  
Documents Incorporated by Reference [Text Block] Part III of this Annual Report on Form 10-K will be incorporated by reference from certain portions of the Registrant’s definitive proxy statement for the 2026 annual meeting of stockholders, or Proxy Statement, or will be included in an amendment hereto, to be filed within 120 days of the end of the fiscal year ended December 31, 2025. Except with respect to information specifically incorporated by reference in this Annual Report on Form 10-K, the Proxy Statement is not deemed to be filed as part hereof.    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Listing, Par Value Per Share $ 0.01    
Auditor Firm ID 274    
Auditor Opinion [Text Block] We have audited the accompanying consolidated balance sheets of Interpace Biosciences, Inc. and Subsidiaries (the “Company”) as of December 31, 2025 and 2024, and the related consolidated statements of operations, stockholders’ equity (deficit), and cash flows for each of the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2025 and 2024, and the consolidated results of their operations and their cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America.    
Auditor Name EISNERAMPER LLP    
Auditor Location Philadelphia, Pennsylvania